Telesis Bio (TBIO)

Executive Summary

Telesis Bio, headquartered in San Diego, is a public synthetic biology company renowned for its Gibson Assembly technology and the BioXp platform, the world's first DNA printer. The company enables rapid, accurate synthesis of large quantities of synthetic genes for academic and commercial researchers. Despite pioneering innovations, Telesis Bio faces intense competition from established players like Twist Bioscience and emerging DNA synthesis startups. The company's valuation is estimated at $97.7 million with only 1.78 million shares outstanding, indicating a micro-cap stature. Recent financial performance has been challenged by market headwinds and slower adoption of its hardware-based model. Nonetheless, Telesis Bio continues to iterate on its BioXp system and expand its reagent kits, positioning itself to capture growth in the synthetic biology market, which is projected to reach $30 billion by 2030.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Generation BioXp System60% success
• TBDStrategic Partnership or Licensing Deal for Gibson Assembly50% success
• Q3 2026Positive Earnings Surprise or Cost-Reduction Announcement40% success